Uncategorized
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma
WELLESLEY, Mass.--(BUSINESS WIRE)--Qlaris Bio today announced the enrollment of the first patient in its Phase 1/2 clinical program for QLS-101.